A detailed history of Nia Impact Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Nia Impact Advisors, LLC holds 71,433 shares of GILD stock, worth $6.44 Million. This represents 1.82% of its overall portfolio holdings.

Number of Shares
71,433
Previous 74,007 3.48%
Holding current value
$6.44 Million
Previous $5.42 Million 9.59%
% of portfolio
1.82%
Previous 2.25%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$63.15 - $72.88 $162,548 - $187,593
-2,574 Reduced 3.48%
71,433 $4.9 Million
Q1 2024

May 15, 2024

SELL
$71.58 - $87.29 $633,483 - $772,516
-8,850 Reduced 10.68%
74,007 $5.42 Million
Q2 2023

Aug 11, 2023

SELL
$76.01 - $86.7 $43,933 - $50,112
-578 Reduced 0.69%
82,857 $6.39 Million
Q1 2023

May 03, 2023

BUY
$77.31 - $88.08 $138,152 - $157,398
1,787 Added 2.19%
83,435 $6.92 Million
Q4 2022

Feb 09, 2023

BUY
$62.32 - $89.47 $451,570 - $648,299
7,246 Added 9.74%
81,648 $7.01 Million
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $962,404 - $1.1 Million
16,164 Added 27.76%
74,402 $4.59 Million
Q2 2022

Aug 05, 2022

BUY
$57.72 - $65.01 $1.06 Million - $1.19 Million
18,283 Added 45.76%
58,238 $3.6 Million
Q1 2022

May 11, 2022

BUY
$57.92 - $72.58 $166,577 - $208,740
2,876 Added 7.76%
39,955 $2.38 Million
Q4 2021

Feb 11, 2022

SELL
$64.88 - $73.64 $261,012 - $296,253
-4,023 Reduced 9.79%
37,079 $2.29 Million
Q3 2021

Nov 16, 2021

BUY
$67.69 - $73.03 $41,967 - $45,278
620 Added 1.53%
41,102 $2.87 Million
Q2 2021

Aug 16, 2021

BUY
$63.47 - $69.35 $60,423 - $66,021
952 Added 2.41%
40,482 $2.79 Million
Q1 2021

Jun 16, 2021

BUY
$60.0 - $68.46 $218,280 - $249,057
3,638 Added 10.14%
39,530 $2.56 Million
Q4 2020

Jan 25, 2021

BUY
$56.65 - $64.55 $2.03 Million - $2.32 Million
35,892 New
35,892 $2.24 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Nia Impact Advisors, LLC Portfolio

Follow Nia Impact Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nia Impact Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nia Impact Advisors, LLC with notifications on news.